SNHG22: A Potential Drug Target for Neurological Disorders (G103091864)

Target Name: SNHG22

NCBI ID: G103091864

SNHG22

Other Name(s): SCARNA17HG | Small nucleolar RNA host gene 22 | SCARNA17 | small nucleolar RNA host gene 22

SNHG22: A Potential Drug Target for Neurological Disorders

SNHG22 (ScarNa17HG) is a protein that is expressed in the nervous system and has been identified as a potential drug target for various neurological disorders. The protein is a key component of the nervous system and is involved in the development, maintenance, and regulation of neuronal communication.

Studies have shown that SNHG22 plays a crucial role in the development and progression of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. In fact,Snhgh22 has been shown to be significantly reduced in the brains of individuals with Alzheimer's disease compared to healthy controls.

Furthermore, SNHG22 has also been shown to be involved in the regulation of pain and inflammation. Studies have shown that SNHG22 can inhibit the production of pain-causing chemicals in the brain, which may have potential as a treatment for chronic pain.

In addition to its potential therapeutic uses, SNHG22 also has important implications for basic research into the biology of the nervous system. The protein is a good candidate for further study as a potential drug target, and research into its function and interactions with other proteins may provide valuable insights into the underlying mechanisms of neurological disorders.

Overall, SNHG22 is a promising candidate for further research as a potential drug target for neurological disorders. Further studies are needed to fully understand its function and potential therapeutic uses.

Protein Name: Small Nucleolar RNA Host Gene 22

The "SNHG22 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNHG22 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets